You have full text access to this OnlineOpen article

A study of the epitopes on steroid 21-hydroxylase recognized by autoantibodies in patients with or without Addison's disease

  1. Volpato1,
  2. Prentice2,
  3. Chen2,3,
  4. Betterle1,
  5. Rees Smith2,3,
  6. Furmaniak2,3

Article first published online: 20 APR 2002

DOI: 10.1046/j.1365-2249.1998.00475.x

Issue

Clinical & Experimental Immunology

Clinical & Experimental Immunology

Volume 111, Issue 2, pages 422–428, February 1998

Additional Information

How to Cite

Volpato, Prentice, Chen, Betterle, Rees Smith and Furmaniak (1998), A study of the epitopes on steroid 21-hydroxylase recognized by autoantibodies in patients with or without Addison's disease. Clinical & Experimental Immunology, 111: 422–428. doi: 10.1046/j.1365-2249.1998.00475.x

Author Information

  1. 1

    Istituto di Semeiotica Medica, University of Padova, Padova, Italy,

  2. 2

    FIRS Laboratories, RSR Ltd.,

  3. 3

    Department of Medicine, University of Wales College of Medicine, Cardiff, UK

* MarinaVolpato MD Istituto di Semeiotica Medica, University of Padova, via Ospedale Civile 105, 35128 Padova, Italy.

Publication History

  1. Issue published online: 20 APR 2002
  2. Article first published online: 20 APR 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (302K)

Keywords:

  • 21-hydroxylase;
  • autoantibodies;
  • Addison's disease;
  • 21-hydroxylase epitopes;
  • polyglandular autoimmune syndromes

Steroid 21-hydroxylase (21-OH) autoantibodies are found in patients with autoimmune Addison's disease (AAD), either isolated or associated with autoimmune polyglandular syndrome (APS) type I and II and in adrenal-cortex autoantibody (ACA)-positive patients without AAD. In order to assess any differences in the 21-OH autoantibodies in these different patient groups, we have studied their reactivity with different epitopes on 21-OH using full length and modified 35S-labelled 21-OH proteins produced in an in vitro transcription/translation system. There were no major differences in the pattern of autoantibody reactivity with the different modified 21-OH proteins in patients with isolated AAD or with APS types I and II, and in 21-OH autoantibody-positive patients with clinical AAD, subclinical AAD and those maintaining a normal adrenal function. Our studies also indicate that the main epitopes for 21-OH autoantibodies in patients with different forms of autoimmune adrenal disease are located in the C-terminal end and in a central region of 21-OH.

View Full Article (HTML) Get PDF (302K)